CD274 and acute myeloid leukemia: Finally, a randomized phase 2 study of azacitidine alone (n = 42) or in combination with the PD-L1 inhibitor durvalumab (n = 42) in older (≥65 years) patients with AML reported similar efficacy for azacitidine alone or in combination, with no new safety signals or potential overlapping risks identified with the combination regimen89.